Comment
doi: 10.1038/nrurol.2013.100.
Epub 2013 May 7.
Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC
- PMID: 23649292
- DOI: 10.1038/nrurol.2013.100
Item in Clipboard
Comment
Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC
Nat Rev Urol.
2013 Jun.
No abstract available
Comment on
-
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.Br J Cancer. 2013 Apr 30;108(8):1571-8. doi: 10.1038/bjc.2013.145. Epub 2013 Apr 11. Br J Cancer. 2013. PMID: 23579211 Free PMC article. Clinical Trial.
-
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598172 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
